ctrl-trade
All companies

LLY vs MRK

Eli Lilly and Company and Merck & Co., Inc., side by side.

On the numbers, LLY leads most core categories in this snapshot.

LLY is growing far faster (revenue 47.7% vs 5.1%), keeps far more of every sales dollar (33.5% net vs 4.8%), and trades at a fraction of the earnings multiple (P/E 38.9x vs 122.3x). Analysts lean the same way — LLY holds a Buy rating and sits roughly 13% below its average price target, while MRK trades near its own. MRK's case rests on a lighter balance sheet (debt-to-equity 1.28x vs 1.62x), steadier price action (beta 0.21x vs 0.51x), and a bigger dividend (2.2% vs 0.6%).

LLY leads on

ValuationProfitabilityGrowthAnalyst upsideReturn on equity

MRK leads on

Balance sheetLower volatilityDividend
Eli Lilly and Company
LLY Drug Manufacturers - General

Eli Lilly and Company

Data as of September 3, 2026
View full LLY profile →
Merck & Co., Inc.
MRK Drug Manufacturers - General

Merck & Co., Inc.

Data as of September 3, 2026
View full MRK profile →

Figures reflect each company's latest snapshot — no metric is a verdict on its own. New to these numbers? Learn how to read them →

Company Size

How large is this company relative to the overall market?

Metric LLY MRK

Company Size

$1.03T · Mega-cap

$374.12B · Mega-cap

Valuation

Is this stock priced cheaply or expensively relative to its earnings and revenue?

Metric LLY MRK

P/E Ratio

38.9x

122.3x

Forward P/E

24.5x

15.9x

Price-to-Sales

13.0x

5.6x

Profitability

How efficiently does the company turn revenue into profit?

Metric LLY MRK

Profit Margin

33.5%

4.8%

Gross Margin

83.4%

75.9%

Return on Equity

102.3%

7.0%

Growth

Is the business expanding — or contracting?

Metric LLY MRK

Revenue Growth

47.7%

5.1%

Earnings Growth

26.2%

Financial Health

Can the company handle its debts and short-term obligations?

Metric LLY MRK

Debt-to-Equity

1.62x

1.28x

Current Ratio

1.35x

1.32x

Dividends

Does the company pay shareholders regular cash income?

Metric LLY MRK

Dividend Yield

0.6%

2.2%

Risk & Volatility

How much does this stock move relative to the overall market?

Metric LLY MRK

Volatility (Beta)

0.51x

0.21x

Analyst View

What do professional Wall Street analysts say about this stock?

Metric LLY MRK

Analyst Consensus

Buy (29 analysts)

Buy (26 analysts)

Analyst Target Price

$1315.04

+13.4% vs price

$148.73

-1.9% vs price

This comparison is a factual summary of reported metrics, not a recommendation to buy, sell, or hold either stock. One company leading on a metric doesn't make it the better investment for you.

Invite Only

Request Your Invite

Ctrl-Trade is invite-only while we're in private beta. Request an invite and we'll reach out when a spot opens up.

Request an Invite